Concepts (142)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Blastomyces | 2 | 2014 | 11 | 0.780 |
Why?
|
| Blastomycosis | 2 | 2014 | 22 | 0.770 |
Why?
|
| Diagnosis, Differential | 5 | 2014 | 318 | 0.540 |
Why?
|
| Breast Neoplasms | 7 | 2019 | 397 | 0.510 |
Why?
|
| Osteomyelitis | 1 | 2014 | 18 | 0.450 |
Why?
|
| Bone Neoplasms | 2 | 2014 | 126 | 0.450 |
Why?
|
| Carcinoma, Lobular | 3 | 2019 | 22 | 0.390 |
Why?
|
| Mastitis | 1 | 2010 | 2 | 0.340 |
Why?
|
| Lupus Erythematosus, Discoid | 1 | 2010 | 8 | 0.330 |
Why?
|
| Immunohistochemistry | 11 | 2019 | 335 | 0.290 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2010 | 171 | 0.280 |
Why?
|
| Wound Healing | 2 | 2018 | 117 | 0.270 |
Why?
|
| Stromal Cells | 2 | 2019 | 33 | 0.260 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2019 | 29 | 0.240 |
Why?
|
| Middle Aged | 14 | 2019 | 7997 | 0.220 |
Why?
|
| Ovarian Neoplasms | 2 | 2016 | 76 | 0.220 |
Why?
|
| Female | 20 | 2019 | 13031 | 0.220 |
Why?
|
| Adult | 15 | 2019 | 7038 | 0.200 |
Why?
|
| Ependymoma | 2 | 2013 | 16 | 0.180 |
Why?
|
| Diabetes Mellitus, Experimental | 2 | 2018 | 19 | 0.180 |
Why?
|
| Adolescent | 5 | 2014 | 1897 | 0.170 |
Why?
|
| Humans | 23 | 2019 | 23152 | 0.170 |
Why?
|
| Retrospective Studies | 6 | 2016 | 3036 | 0.160 |
Why?
|
| Fibroblasts | 1 | 2019 | 50 | 0.160 |
Why?
|
| Cell Nucleus | 3 | 2016 | 70 | 0.150 |
Why?
|
| Cytoplasm | 3 | 2014 | 33 | 0.150 |
Why?
|
| Biomarkers, Tumor | 5 | 2016 | 200 | 0.150 |
Why?
|
| Male | 12 | 2018 | 12524 | 0.150 |
Why?
|
| Low-Level Light Therapy | 1 | 2018 | 4 | 0.140 |
Why?
|
| Culture Media, Conditioned | 1 | 2018 | 18 | 0.140 |
Why?
|
| Photosensitizing Agents | 1 | 2018 | 4 | 0.140 |
Why?
|
| Wound Infection | 1 | 2018 | 6 | 0.140 |
Why?
|
| Curcumin | 1 | 2018 | 6 | 0.140 |
Why?
|
| Panniculitis | 2 | 2010 | 5 | 0.140 |
Why?
|
| Pleural Effusion | 2 | 2016 | 14 | 0.140 |
Why?
|
| Young Adult | 2 | 2014 | 1713 | 0.130 |
Why?
|
| Pelvic Neoplasms | 1 | 2016 | 8 | 0.130 |
Why?
|
| Granulosa Cell Tumor | 1 | 2016 | 4 | 0.130 |
Why?
|
| Pericardial Effusion | 1 | 2016 | 6 | 0.130 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2016 | 193 | 0.130 |
Why?
|
| Ascitic Fluid | 1 | 2016 | 10 | 0.130 |
Why?
|
| Liver Neoplasms | 2 | 2016 | 103 | 0.130 |
Why?
|
| Multiple Myeloma | 1 | 2016 | 16 | 0.130 |
Why?
|
| Staphylococcal Infections | 1 | 2018 | 157 | 0.120 |
Why?
|
| Neoplasm Proteins | 2 | 2014 | 51 | 0.120 |
Why?
|
| Aged | 10 | 2019 | 7448 | 0.120 |
Why?
|
| Frozen Sections | 1 | 2014 | 14 | 0.110 |
Why?
|
| Pathology | 1 | 2014 | 2 | 0.110 |
Why?
|
| Angiolipoma | 1 | 2014 | 2 | 0.110 |
Why?
|
| Receptors, Androgen | 1 | 2014 | 6 | 0.110 |
Why?
|
| Predictive Value of Tests | 4 | 2010 | 419 | 0.110 |
Why?
|
| Hemangioma | 1 | 2014 | 8 | 0.110 |
Why?
|
| Adipocytes | 1 | 2014 | 22 | 0.110 |
Why?
|
| Peripheral Nervous System Neoplasms | 1 | 2013 | 4 | 0.110 |
Why?
|
| Biopsy, Fine-Needle | 2 | 2004 | 62 | 0.110 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2014 | 17 | 0.110 |
Why?
|
| Intraoperative Care | 1 | 2014 | 39 | 0.110 |
Why?
|
| Hemangiosarcoma | 1 | 2014 | 10 | 0.110 |
Why?
|
| Lymphatic Metastasis | 4 | 2014 | 86 | 0.100 |
Why?
|
| Lymph Nodes | 2 | 2003 | 70 | 0.100 |
Why?
|
| Neoplasm Invasiveness | 3 | 2019 | 90 | 0.100 |
Why?
|
| Lung Neoplasms | 1 | 2016 | 543 | 0.090 |
Why?
|
| Aged, 80 and over | 7 | 2019 | 3711 | 0.090 |
Why?
|
| Microbiological Techniques | 1 | 2010 | 6 | 0.080 |
Why?
|
| Receptor, ErbB-2 | 2 | 2016 | 52 | 0.080 |
Why?
|
| Papilloma | 1 | 2009 | 4 | 0.080 |
Why?
|
| Alphapapillomavirus | 1 | 2009 | 6 | 0.080 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2009 | 32 | 0.080 |
Why?
|
| Cytological Techniques | 1 | 2009 | 14 | 0.080 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2009 | 10 | 0.080 |
Why?
|
| Rats, Wistar | 2 | 2018 | 46 | 0.070 |
Why?
|
| Reproducibility of Results | 1 | 2010 | 596 | 0.070 |
Why?
|
| Rats | 2 | 2018 | 609 | 0.060 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 1 | 2004 | 5 | 0.060 |
Why?
|
| Receptors, Estrogen | 3 | 2016 | 62 | 0.060 |
Why?
|
| Papilloma, Inverted | 1 | 2004 | 16 | 0.050 |
Why?
|
| Lymphatic Diseases | 1 | 2003 | 4 | 0.050 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2004 | 39 | 0.050 |
Why?
|
| Paget's Disease, Mammary | 1 | 2003 | 2 | 0.050 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 2004 | 59 | 0.050 |
Why?
|
| Breast | 1 | 2002 | 23 | 0.050 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2004 | 162 | 0.050 |
Why?
|
| Lymphoma, T-Cell | 1 | 2002 | 4 | 0.050 |
Why?
|
| Rhabdomyosarcoma | 1 | 2002 | 8 | 0.050 |
Why?
|
| Abdominal Neoplasms | 1 | 2002 | 15 | 0.050 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2002 | 9 | 0.050 |
Why?
|
| Breast Neoplasms, Male | 1 | 2002 | 11 | 0.050 |
Why?
|
| Combined Modality Therapy | 2 | 2018 | 293 | 0.050 |
Why?
|
| Nuclear Proteins | 1 | 2002 | 74 | 0.050 |
Why?
|
| Receptors, Progesterone | 2 | 2016 | 26 | 0.040 |
Why?
|
| Neoplasms | 1 | 2003 | 215 | 0.040 |
Why?
|
| Kidney Transplantation | 1 | 2002 | 107 | 0.040 |
Why?
|
| Animals | 2 | 2018 | 3253 | 0.040 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2019 | 6 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2016 | 449 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2019 | 127 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2019 | 101 | 0.040 |
Why?
|
| Cell Movement | 1 | 2019 | 76 | 0.040 |
Why?
|
| Lasers | 1 | 2018 | 14 | 0.040 |
Why?
|
| Bone Marrow Cells | 1 | 2018 | 50 | 0.040 |
Why?
|
| Biopsy, Needle | 3 | 2002 | 101 | 0.040 |
Why?
|
| Staphylococcus aureus | 1 | 2018 | 70 | 0.030 |
Why?
|
| Skin | 1 | 2018 | 118 | 0.030 |
Why?
|
| Vacuoles | 1 | 2016 | 7 | 0.030 |
Why?
|
| Karyotype | 1 | 2016 | 2 | 0.030 |
Why?
|
| Immunoglobulin A | 1 | 2016 | 13 | 0.030 |
Why?
|
| Syndecan-1 | 1 | 2016 | 5 | 0.030 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2018 | 113 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2018 | 514 | 0.030 |
Why?
|
| Extracellular Space | 1 | 2014 | 10 | 0.030 |
Why?
|
| 12E7 Antigen | 1 | 2013 | 3 | 0.030 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2013 | 12 | 0.030 |
Why?
|
| Cell Adhesion Molecules | 1 | 2013 | 15 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2013 | 28 | 0.030 |
Why?
|
| Neovascularization, Pathologic | 1 | 2014 | 30 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2013 | 49 | 0.030 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2013 | 38 | 0.030 |
Why?
|
| Carcinoma | 1 | 2013 | 66 | 0.030 |
Why?
|
| Ki-67 Antigen | 2 | 2002 | 17 | 0.020 |
Why?
|
| Multivariate Analysis | 2 | 2002 | 284 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2009 | 114 | 0.020 |
Why?
|
| Genotype | 1 | 2009 | 247 | 0.020 |
Why?
|
| Nuclear Envelope | 1 | 2004 | 3 | 0.010 |
Why?
|
| Gene Amplification | 1 | 2003 | 21 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2003 | 36 | 0.010 |
Why?
|
| False Negative Reactions | 1 | 2002 | 13 | 0.010 |
Why?
|
| Axilla | 1 | 2002 | 13 | 0.010 |
Why?
|
| False Positive Reactions | 1 | 2002 | 31 | 0.010 |
Why?
|
| Antigens, Nuclear | 1 | 2002 | 4 | 0.010 |
Why?
|
| Biopsy | 1 | 2002 | 192 | 0.010 |
Why?
|
| Cell Cycle | 1 | 2002 | 33 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2002 | 223 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2002 | 119 | 0.010 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2002 | 85 | 0.010 |
Why?
|
| Logistic Models | 1 | 2002 | 341 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2002 | 114 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2002 | 355 | 0.010 |
Why?
|
| Liver | 1 | 2002 | 141 | 0.010 |
Why?
|
| Age Factors | 1 | 2002 | 635 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2002 | 563 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2002 | 600 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2004 | 3038 | 0.010 |
Why?
|